The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Ergomed plc

9 Oct 2023 11:45

RNS Number : 4350P
JPMorgan Asset Management
09 October 2023
 
FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

JPMorgan Asset Management

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Ergomed plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

06 October 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

428,272

0.84

0

0.00

(2) Cash-settled derivatives:

 

369,032

0.72

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

797,304

1.56

0

0.00

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary Shares

Sale

43,000

13.4100 GBP

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

none

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

none

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

 

Date of disclosure:

09 October 2023

Contact name:

 

Natasha Mondon

Telephone number*:

 

01202 325175

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETUKSRROAURRAA
Date   Source Headline
4th Apr 20227:00 amRNSIssue of Consideration Shares
1st Apr 202211:25 amRNSTotal Voting Rights
29th Mar 20227:00 amRNSErgomed Preliminary Results 2021
9th Mar 20227:00 amRNSJohn Dawson CBE Appointed to Ergomed Board as NED
1st Mar 20227:00 amRNSTotal Voting Rights
28th Feb 20227:00 amRNSErgomed Notice of Preliminary Results
11th Feb 20224:06 pmRNSDirector's Dealing
9th Feb 20227:00 amRNSAcquisition of ADAMAS
2nd Feb 20225:47 pmRNSHolding(s) in Company
25th Jan 20227:00 amRNSErgomed 2021 Trading Update
4th Jan 20227:00 amRNSTotal Voting Rights and Block Listing Return
1st Dec 20217:00 amRNSTotal Voting Rights
25th Nov 20217:00 amRNSExercise of Options
23rd Nov 20211:10 pmRNSHoldings in Company
15th Nov 20217:00 amRNSErgomed to Present at Jefferies Conference 2021
1st Nov 20217:00 amRNSTotal Voting Rights
25th Oct 20217:00 amRNSExercise of Share Options and Total Voting Rights
21st Oct 202110:20 amRNSHolding(s) in Company
5th Oct 20217:10 amEQSErgomed (ERGO): US is now the biggest market in the mix
5th Oct 20217:01 amEQSCreo Medical (CREO): Initiation - Providing energy for endoscopic surgery
1st Oct 20217:00 amRNSTotal Voting Rights
28th Sep 20217:00 amRNSErgomed Interim results
1st Sep 20217:00 amRNSTotal Voting Rights
23rd Aug 20217:00 amRNSNotice of Interim Results
19th Aug 202112:06 pmRNSHolding(s) in Company
18th Aug 202112:24 pmRNSHolding(s) in Company
18th Aug 202112:09 pmRNSDirector dealings
12th Aug 20217:01 amEQSErgomed (ERGO): Momentum continues with EBITDA upgrades
2nd Aug 20217:00 amRNSTotal Voting Rights
27th Jul 20217:00 amRNSTrading Update
19th Jul 20217:00 amRNSAppointment of Joint Corporate Broker
1st Jul 20217:00 amRNSBlock listing Interim Review
1st Jul 20217:00 amRNSTotal Voting Rights
17th Jun 20214:28 pmRNSHolding(s) in Company
17th Jun 20217:05 amRNSBoard Change
14th Jun 20218:14 amEQSErgomed (ERGO): FY21e EBITDA 'materially ahead' of consensus
10th Jun 202110:00 amRNSResult of AGM
10th Jun 20217:00 amRNSAGM Statement
2nd Jun 20218:00 amEQSEdison Investment Research Limited: Ergomed (ERGO): What's next after stellar 2020 performance?
1st Jun 20217:00 amRNSTotal Voting Rights
28th May 20217:00 amRNSErgomed to Present at Jefferies Conference
14th May 202111:30 amRNSHolding(s) in Company
14th May 20217:00 amRNSNotice of AGM and Annual Report
10th May 20217:00 amRNSBoard Changes
4th May 20217:00 amRNSTotal Voting Rights
29th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSBoard Changes
26th Apr 20217:00 amRNSErgomed expands operations in Japan
1st Apr 20217:00 amRNSTotal Voting Rights
23rd Mar 20217:00 amRNSAudited Full Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.